Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HexaPro - Vaxxas

Drug Profile

HexaPro - Vaxxas

Alternative Names: HexaPro HD-MAP vaccine; HexaPro SARS-COV2 Vaccine; SARS-CoV-2 Spike Vaccine

Latest Information Update: 12 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas at Austin
  • Developer Griffith University; University of Queensland
  • Class COVID-19 vaccines; Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I COVID 2019 infections

Most Recent Events

  • 06 Jun 2023 Interim safety data from a phase I trial in COVID-19 infections released by Vaxxas
  • 06 Jun 2023 Pharmacodynamics data from a preclinical studies in COVID-19 infections released by Vaxxas
  • 06 Jun 2023 Vaxxas completes enrolment in its phase I trial for COVID-19 infections (Prevention, In volunteers) in Australia (Transdermal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top